[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593560":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":24,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":10,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"St. Jude Children's Research Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Non-protocol therapy \u002Fstandard of care therapy",null,"Participants receiving non -protocol standard if care (SOC) treatment.",{"label":13,"type":10,"description":14,"interventionNames":10},"SJALL23T (NCT06390319) protocol therapy","Participants receiving protocol therapy on SJALL23T and not receiving investigational drug.",[16],{"name":17,"affiliation":5,"role":18},"Seth E. Karol, MD, MSCI","PRINCIPAL_INVESTIGATOR",[20],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","888-226-4343","referralinfo@stjude.org",[25],{"facility":5,"status":10,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Memphis","Tennessee","38105","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-90.04898,35.14953,{"lat":35,"lon":34},[38,40],{"name":39,"role":21,"phone":22,"phoneExt":10,"email":23},"Seth E. Karol",{"name":17,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100593560","real-world-asparaginase-therapy-toxicity-100593560",false,"NCT07008027","Real World Asparaginase Therapy Toxicity","Inclusion Criteria:\n\n* Diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia\n* Enrolled on INITIALL and no more than 10 days after initiation of post-INITIALL therapy\n* Post-INITIALL therapy is:\n\n  * Standard of Care (SOC)\u002FNon Protocol Treatment Plan (NPTP) as per Total therapy or\n  * SJALL23T and not scheduled to receive venetoclax\n\nExclusion Criteria:\n\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.","ALL",{"count":51,"type":52},200,"ESTIMATED","OBSERVATIONAL","This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy) therapy.",[56],"Drug Toxicity",[58,59,60,61,62],"Asparaginase drugs","Toxicity","Acute lymphoblastic leukemia","Acute lymphoblastic lymphoma","Mixed phenotype acute leukemia","NOT_YET_RECRUITING","2026-06-29",{"date":66,"type":67},"2026-07-01","ACTUAL",{"date":69,"type":52},"2026-07",{"date":71,"type":52},"2031-07",{"name":5,"class":6},1]